Ann: Quarterly Activities Report and Appendix 4C, page-5

pretty disappointing update. not sure how the market will take this.

Biggest issue is the change in excepted approval for the Prizma in China from "mid 2020" to "CY 2020". So another 6 month delay?

A lot of fluff around the US business and how well it is doing. We basically it hasn't been doing that well. The company needs to provide growth numbers normalised for acquisitions. You can't blame Thanks Giving and Christmas holidays. Did they not occur in 2018?

Last few quarterly revenue numbers:

Dec 19 - $1.404m
Sept 19 - $1.478m
June 19 - $1.314m
Mar 19 - $1.226m
Dec 18 - $1.348m
Sept 18 - $0.671m

So comparing Dec 18 to Dec 19 revenue grew by 4.15%

Anyway, will be interesting to see what that "announcement" Yacov has up his sleeve in "early" Feb. Not sure how the ASX lets you get away with this!

At least the company has the funding in place. Will just be a case of what price new shares are issued and how much existing shareholders get diluted.